News
Netris Pharma starts hepatocellular carcinoma study
Netris Pharma – a company developing drugs based on dependence receptor biology – has announced that the first patients have been dosed in a multicentre, single arm, proof-of-concept trial of the anti-netrin-1 antibody, NP137, in combination with atezolizumab-bevacizumab (Atezo-bev).